
INDEX

- Acquired Immune Deficiency Syndrome (AIDS), 399
- activities of daily living (ADL)
 assessments, 253
- acute graft vs. host disease (aGVHD)
 with apoptosis, 94
 in B6 animal model, 32
 cGVHD vs., 31, 71, 89–91.
 (See also overlap syndrome)
 DLI associations with, 31, 56
 effector phase, 12
 induction by mature $\alpha\beta$ T cells (in donor allograft), 37
 pathophysiology of
 cGVHD vs., 31
 three-step model
 effects of HCT conditioning, 8, 9
 donor T-cell activation/cytokine secretion, 8–11
 cellular and inflammatory effectors, 8, 11–13
 pediatric patients, 369
 peripheral blood elevations, 12
 phototherapy treatment, 140–141, 176
 risk factors, 71
 staging for, 147
 as Th1 disease, 80
- acute leukemia, 361
- acute lymphoblastic leukemia (ALL), 369
- acute respiratory distress syndrome, 243
- acyclovir, 129, 162, 163, 164, 223, 276
- adenovirus, 221, 273, 277, 308
- adrenal insufficiency, 292–293
- adult-thymectomized BALB/c recipients, 18
- advocacy for patients
 chronic lymphocytic leukemia (case study), 396–397
 cross-community relationships, 399
 impact of cGVHD, 397–398
 Institute of Medicine (IOM) Report, 398
 nonprofit (NPO) organizations, 398–399
- patient education, 399–402
 peer support, 402–403
 public policy, 403–404
- Aeromonas*, 277
- age considerations, 17
- alemtuzumab, 223, 362
- alendronate, 162, 163, 256–257
- allogenic hematopoietic stem cell transplantation (allo-HSCT), 31, 33, 71
 and Scl-cGVHD, 37
- allo-HSCT. See allogenic hematopoietic stem cell transplantation
- alpha-1 antichymotrypsin, 79
- alpha-1 antitrypsin (AAT), 79
- American Academy of Oral Medicine (website), 189
- American College of Rheumatology Ad Hoc Committee, 256–257
- American College of Sports Medicine, 258
- American Nurses Association, 404
- American Society for Blood and Marrow Transplantation, 400
- American Society of Clinical Oncology (ASCO), 400, 404
- amikacin for *Nocardia* infection, 273
- ancillary and supportive care
 case histories
 CY/12 GyTBI conditioning/PBT for AML, 163–164
 myeloablative conditioning/PBT for CML, 164–165
 myeloablative conditioning/PBT for MDS/RA, 159–162
 PBT from HLA-matched sister, 162–163
 defined, 157
 evidence-based rating system, 158–157
 organ system monitoring, 157, 158–161
 prevention focus, 157–160
- Ancillary Therapy and Supportive Care Working Group (of NIH), 157
- angiotensin II receptor blockers (ARBs), 295
- angiotensin-converting enzyme inhibitors (ACEIs), 295
- angular cheilitis, 191
- animal models of cGVHD. See also mouse models
 B10.D2 (or B6.C)gBALB/c model, 34–36
 effector phase, 35
 induction phase, 34–35
 initial description, 34
 mast cells, 35
 reasons for choosing, 35–36
 cGVHD autoimmunity determination, 37–40
 DBA/2gBALB/c with sublethal irradiation/no BM rescue, 37
 parentgF1 models, 32–34
 common features, 32
 Scl-GVHD model, 37
- antibacterial drugs. See metronidazole; norfloxacin
- anti-cardiolipin antibody, 20
- anti-CD20 chimeric monoclonal antibodies, 33, 48. See also rituximab
- anti-cytokine therapy
 minimal usage of, 142
 for pediatric cGVHD, 379
- anti-dsDNA antibody, 20, 22
- anti-epileptic agents, 107, 127
- antigen presenting cells (APCs), 8. See also dendritic cells (DCs)
 allogenic donor T cell activation, 8, 34
 BALB/c antigens, 34
 donor APCs (plasmacytoid DC2 cells), 75, 177
 elimination by natural killer (NK) cells, 10, 34
 importance of, in cGVHD development, 19
 MHCII+, 35
 study approach, 34

410 ■ INDEX

- antimicrobial drugs, 127, 270, 272, 376
- anti-mitochondrial antibody, 20, 22
- anti-neutrophil antibody, 20
- anti-nuclear antibody (ANA), 20, 22
- anti-smooth muscle antibody, 20
- antithymocyte globulin (ATG), 17, 48, 362, 377
- APCs. *See* antigen presenting cells
- aplasia-associated complications, 3
- aplastic anemia
- from HLA identical sibling donors, 46, 71
 - HSCT for, 6
 - MG development and, 245
- apoptosis, 31
- aGVHD with, 94
 - B cell receptor triggering, 19
 - CTL induction, 11
 - epithelial, induction by TNF- α , 8
 - Fas-mediated, of activated donor T-cells, 11
 - of target cells, 8
- Aquaphor[®] petroleum-based emollient, 176
- arcuate vaginal synechiae, 208
- arrhythmias, 307
- aspergillus, 109, 268, 271, 277
- assessment (clinical) of cGVHD, 56–66.
- See also* evaluation of cGVHD; monitoring of cGVHD
 - eyes, 57, 64–65, 66–67
 - focused medical history, 57
 - KPS score, 73, 89, 125, 137, 147
 - Lee Symptom Scale, 152
 - lungs, 66
 - mouth, 61
 - mouth evaluation, 57, 61
 - musculoskeletal/joints, 57, 66
 - skin/dermal appendages, 57–61
- Association of Cancer Online Resources, 403
- Association of Community Cancer Centers, 404
- astrovirus, 277
- athymic BALB/c (nu/nu) recipients, 18
- atomic bomb radiation exposure, 3
- atovaquone suspension for *Pneumocystis jiroveci*, 276
- autoantibodies, 17, 20, 32, 48
- ANA, 22, 32
 - arthralgia/arthritis association, 92
 - in B6gB6^{bm12}/B6^{bm12}gB6 model, 32
 - B-cell dysfunction association, 379
 - H-Y antigen, 20
 - myasthenia gravis association, 245, 302
 - PDGFR- α autoantibodies, 20
 - in PgF1 models, 33
 - platelet bound, in persistent thrombocytopenia, 240
 - serum test for CYP1A2, 223
 - stimulatory, to PDGF, 37, 179
 - T-1 helper cells production of, 6
- autoimmune hemolytic anemia (AIHA), 240–241
- autoimmunity and cGVHD, 6
- avascular necrosis, 127, 257
- definition/incidence, 291
 - pathophysiology/risk factors, 291
 - as secondary/late effect, 328
 - treatment, 291–292
- azathioprine, 125, 128, 135
- for retroperitoneal fibrosis, 311
 - for squamous cell carcinoma, 330
 - topical, for oral mucosal cGVHD, 191
 - for vasculitis, 304
- azithromycin, 235, 279
- for COP/BOS, 235
- azole drug class. *See* fluconazole; itraconazole; ketoconazole; posaconazole; voriconazole
- B6 (H-2b)gB6xDBAF1 (B6D2F1) strain pairing, 32
- B6^{bm12}gB6xB6^{bm12} strain pairing, 32
- B6gB6D2F1 model, 32
- B10.D2 (or B6.C)gBALB/c animal model, 34–36
- effector phase, 35
 - induction phase, 34–35
 - initial description, 34
 - mast cells, 35
 - reasons for choosing, 35–36
- B10.D2g BALB/c Scl-GVHD model vs. clinical cGVHD, 37
- bacterial infections in cGVHD, 46, 129, 271, 272–273
- antibiotic prophylaxis, 129
 - commonness of, 268
 - increased risks in, 268
 - MMF for, 109
 - 1970–1980 data, 46
 - prevention of, 278–280
 - antifungal prophylaxis, 280–281
 - antiviral prophylaxis, 281–282
 - community-acquired respiratory viruses (with antiviral agents), 282
 - IV immunoglobulin, 278–279
 - pneumocystis jiroveci prophylaxis, 281
 - prophylactic antibiotics, 279–280
 - VZV/HSV prophylaxis, 282
 - of the skin, 276
 - treatment of, 277
- BALB/c (H-2d) recipients. *See also* adult-thymectomized BALB/c recipients; athymic BALB/c (nu/nu) recipients; cgBALB/c recipients
- nedocromil sodium stabilization of mast cells, 35
 - second transplants, 34
- basal cell carcinoma (BCC), 330
- B-cell activating factor (BAFF), 19, 81
- soluble BAFF (sBAFF), 22
- B-cells
- acquisition of miHAs, 37
 - function assessment, 81
 - recipient, interacting with CD4 cells, 32–33
 - role in GVHD pathophysiology, 19, 48
 - triggering of apoptosis, 19
- beclomethasone dipropionate (BDP), 222, 224
- biliary and gallbladder problems, 224–225
- Billingham, R. E., 4
- biomarkers in cGVHD, 21–22
- defined, 79
 - for prediction/monitoring
 - B cell function assessment, 81
 - genetic markers, 80
 - serum/cellular cytokine production and Th1/Th2 paradigm, 79–80
 - T cell function assessment, 80–81 - role of Tregs, 21
- Biomarkers Working Group, 21–22
- bisphosphonates, 130, 162. *See also* alendronate; risedronate
- for AVN treatment, 291
 - for bone loss prevention, 256
 - for glucocorticoid-induced osteoporosis, 157
 - for pediatric patients, 328
 - vs. inappropriate HRT, 290
- blepharitis, 92, 201–202
- Blood and Marrow Transplant Clinical Trials Network, 51
- BMT InfoNet, 399, 403
- BMT-Talk (list-serv), 403
- bone marrow aplasia, 3, 238
- Bone Marrow Survivor Study (BMT-SS) questionnaire, 253
- bone marrow transplants (BMTs)
- CNS/PNS dysfunction risks, 257–258
 - 1980–1990 data, 46–48
 - peripheral blood transplants vs., 52–53, 120
- bone metabolism
- osteopenia and osteoporosis
 - definitions/incidence, 289
 - pathophysiology/risk factors, 289
 - treatment, 289–291
- bone mineral density (BMD)
- DEXA measurements, 289
 - hormone replacement therapy and, 290
- BOOP. *See* bronchiolitis obliterans organizing pneumonia (BOOP)
- BOS. *See* bronchiolitis obliterans syndrome (BOS)
- bowel GVHD, 34, 35
- bradyarrhythmias, 307, 308
- breast cancer, 318, 328, 399

- bronchiolitis obliterans organizing pneumonia (BOOP), 216, 229
- bronchiolitis obliterans syndrome (BOS), 31, 37, 56, 67
- clinical manifestations, 234
- diagnostic criteria, 91, 234
- risk factors/epidemiology, 233
- therapy/outcome, 234–235
- w/wo organizing pneumonia, 31
- budesonide, enteric-coated, 222
- bulbar conjunctival hyperemia (“red eye”), 201
- busulfan/cyclophosphamide myeloablative regimens, 52
- C. difficile*, 277
- cachexia, 12, 108
- calcineurin inhibitors, 104–108, 127, 135.
- See also cyclosporine; tacrolimus
- drug interactions, 107–108
- pharmacokinetics
- absorption, 106
- distribution, 106–107
- metabolism, 107
- pharmacology
- clinical pharmacology, 106
- mechanism of action, 105–106
- posterior leukoencephalopathy from, 247
- with prednisone, 101
- toxicity, 108
- calcium channel blockers, 107, 127, 295
- calcium supplementation, 162, 163, 164, 165
- Campath-1H antibody prophylaxis, 17, 48, 117
- Campylobacter*, 277
- cancer-related issues
- basal cell carcinoma (BCC), 330
- cancer-related fatigue (CRF), 259
- Childhood Cancer Survivor Study, 253
- early onset vs. secondary cancer, 330
- Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale, 253
- mucosal carcinoma, 330–331
- radiation related cancers, 330
- secondary cancer surveillance, 194
- skin/mucosal carcinoma, 330–331
- squamous cell carcinoma, 330
- thyroid carcinoma, 331
- candidiasis, oral, 183, 191
- cardiac involvement, in cGVHD
- diagnosis, 308
- future directions, 308–309
- incidence, 306
- presentation, 307–308
- prognosis/clinical course, 308
- cataracts, 126–127, 326–327
- CD4 cells, interacting with recipient B cells, 32–33
- CD4+CD25+ regulatory T cells, 11, 20
- sCD13 antigen, 20
- CD20 antagonists (rituximab), 141
- CD28-mediated down-regulation of I κ B α , 110
- CD31 antigen, 20
- CD80 costimulatory molecule, 10
- CD86 costimulatory molecule, 10
- ceftriaxone for Nocardia infection, 273
- cellular and inflammatory effectors, 11–13
- cellular effectors, 11–12
- inflammatory effectors, 12
- TLRS and innate immunity, 12–13
- traffic of cellular effectors, 13
- central nervous system (CNS)
- manifestations of cGVHD, 277–278
- demyelinative disease, 247–249
- determination of cGVHD reality, 246–248
- immune-mediated encephalitis, 249–250
- proposed diagnostic criteria, 247–249
- stroke from vasculitis/angiitis, 249
- cerebral vasculitis, 304
- cevimeline, 129
- cgBALB/c recipients, 34
- cgBALB/c (H-2d) recipients, 34
- cGVHD. See chronic graft vs. host disease (cGVHD)
- cheilitis, angular, 191
- Childhood Cancer Survivor Study, 253
- children. See pediatric cGVHD
- Children’s Oncology Group study, 18
- chloroquine, 19–20. See also hydroxychloroquine (HCQ)
- chronic graft vs. host disease (cGVHD). See also cutaneous cGVHD; gastrointestinal GVHD; genital cGVHD; hepatic cGVHD; pathophysiology of chronic graft vs. host disease; sclerodermatous GVHD; steroid-resistant cGVHD; syngeneic GVHD
- aGVHD vs., 31, 71, 89–91. (See also overlap syndrome)
- assessment. (See assessment (clinical) of cGVHD)
- autoimmunity and, 6
- determination of, 37–40
- as barrier to allo-HSCT, 31
- clinical, vs. B10.D2g BALB/c Scl-GVHD model, 37
- defined/described, 5–4, 17, 56
- diagnosis. (See diagnostic criteria for establishment of cGVHD)
- DLI associations with, 31, 56
- dynamics of, 94–95
- effector phase, of skin GVHD, 35
- evolution of, 31
- and graft vs. leukaemia effects, 6
- impact of HRQOL on, 56, 68, 341–342
- as late altered immunity, 6
- limited/extensive, 72–73, 88
- monitoring of, 66–68
- morbidity/mortality burden, 341–342
- onset after HSCT, 56
- photographic evaluation, 67–68
- phototherapy treatment, 140–141, 176
- political effects (in late 1970s), 4
- predictive models for prognosis of, 72–74
- risk factors. (See risk factors for cGVHD development)
- symptoms mislabeled as, 57
- as Th2 disease, 80
- chronic GVHD antigens, 20
- chronic inflammatory demyelinating neuropathy (CIDN), 245–246, 257
- chronic lymphocytic leukemia (CLL) case study, 396–397
- chronic myeloid leukemia, 6, 72, 229, 361
- chronic obstructive lung disease, 327
- chronic obstructive pulmonary disorder (COP), 229, 230
- cicatricial ectropion (of eyelids), 201–202
- CIDN. See chronic inflammatory demyelinating neuropathy (CIDN)
- cirrhosis, primary biliary, 56
- cisplatin vs. thalidomide, 246
- City of Hope National Medical Center study, 377
- clarithromycin, 104
- Class II invariant chain peptide (CLIP), 40
- classification system, 74
- historical background, 87–89
- ideal system characteristics, 87
- Seattle group, 89
- clindamycin for *Pneumocystis jiroveci*, 276
- clinical cGVHD vs. B10.D2g BALB/c Scl-GVHD model, 31
- clinical trials for treatment testing
- biostatistical considerations
- missing data, handling of, 357
- prevention trials, 356–357
- treatment trials, 357
- data collection
- adverse (AE)/serious adverse events (SAE), 354
- case reports forms, 353–354
- multi-institutional study
- considerations, 354
- patient-reported outcomes, 354
- timing, 353
- drug development considerations, 352
- FDA review of studies, 357–358
- future challenges, 358
- participant selection
- exclusion criteria, 352
- general considerations, 351–352
- primary and secondary endpoints
- disease activity vs. damage, 355

412 ■ INDEX

- clinical trials for treatment testing (cont.)
 physician/patients, supporting
 information, 355–356
 response as an endpoint, 355
 selection of, 354–355
 treatment methods
 ancillary therapy/supportive
 care, 353
 cGVHD evaluation/management, 352
 glucocorticoid administration, 353
 interventions/medication
 administration, 353
- clinimetrics, 148
- clobetasol 0.05% cream/ointment
 for cutaneous cGVHD, 176
 for genital cGVHD, 212
- clobetasol 0.05% cream/ointment (for
 cutaneous cGVHD), 176
- clofazimine, 141
- clotting factors in cGVHD, 238, 240
- coagulation system abnormalities in
 cGVHD, 238
- cobweb vaginal synechiae, 208
- cognitive effects of cGVHD treatment,
 316–317
 concentration, 316–317
 memory, 316
 mood, 317
- Cognitive Neuroscience (COG) study,
 23–24
- colon disorders. *See* stomach, small
 intestine, colon disorders
- Common Terminology Criteria for
 Adverse Events, ver. 3.0 (CTC
 AE v3.0), 202
- complications
 aplasia-associated, 3
 endothelial, 12
 esophageal (of gastrointestinal cGVHD)
 diagnosis, 217–218
 future advances, 219
 incidence, 216
 presentation, 216
 prevention, 218–219
 significance for prognosis, 216
 therapy, site-specific, 218
- fasciitis, contractures, serositis, 125
- of glucocorticoid treatment, 129
- hematologic
 clotting factors, 240
 coagulation system abnormalities, 238
 cytopenia, patient evaluation, 238
 red blood cell abnormalities,
 240–241
 thrombocytopenia, 238–240
 venous thromboembolism, 240
 white blood cell abnormalities, 241
- infections, 80, 117
- of methylprednisolone/CsA, 120
- ophthalmological, 66–67
- of prednisone (high-dose), 126–127
- pulmonary, 80, 125. (*See also*
 bronchiolitis obliterans)
 fibrosing, 179
 non-infectious, 270, 271, 272
 of rehabilitation
 contractures, 258–259
 edema, 260–262
 fatigue, 259–260
 of steroid treatments, 125
- conjunctivitis
 pseudomembranous conjunctivitis, 199
 pseudomembranous
 keratoconjunctivitis, 202
 superior limbic keratoconjunctivitis,
 201
- connective tissue tumors, 330
- Consensus Development Project on
 Criteria for Clinical Trials in
 cGVHD (of NIH)
 ancillary/supportive care guidelines,
 157
 on cGVHD biomarkers, 21
 COP/BOS recommendations, 229
 criteria development procedures, 94
 cutaneous cGVHD proposed
 criteria, 169
 drug development recommendations,
 351
 ocular GVHD scoring system, 202
 oral cGVHD standardized criteria, 187
 on predictive categories, 125
 standardization attempts, 53
- constitutional syndrome, 273
- coronary artery disease, 307
- coronary heart disease (CHD), 328
- corticosteroids, 101–104
 drug interactions, 104
 for dysphagia/right hemiparesis, 249
 for oral cGVHD, 188–189
 pharmacokinetics
 absorption, 103
 distribution, 103
 metabolism, 103–104
- pharmacology
 genomic mechanisms, 101
 immunosuppression mediation,
 101–103
 nongenomic mechanisms, 103
 pulse corticosteroid therapy, 103
 rituximab with, 240
 survival rate improvement from, 146
- topical
 for cutaneous cGVHD, 176
 for oral mucosal cGVHD, 190–191
 for vaginal restenosis, 211
- toxicity, 104
- CpG ODNs
 aggravation of GVHD severity, 19
- critical illness polyneuropathy (CIPN), 246
- cryptogenic organizing pneumonia
 clinical manifestation, 231–232
- diagnostic criteria, 231–233
 risk factors/epidemiology, 231
 therapy and outcome, 231–233
- Cryptosporidium*, 277
- CTLs. *See* cytotoxic T lymphocytes
- Cushing's syndrome (iatrogenic)/adrenal
 insufficiency, 292–293
 definition/incidence, 292–293
 treatment, 293
- cutaneous cGVHD. *See also* skin fibrosis
 diagnosis, 171–175
 diagnostic criteria/features, 169–171
 distinctive criteria, 91–92
 effector phase, 35
 future research directions, 178–179
 histologic studies, 96–97
 manifestations of, 169–19
 in pediatric patients, 373–374
 prevention of, 178
 prognosis/clinical course, 171
 resembling dermatological
 conditions, 172
 skin/dermal appendage assessment,
 57–61
 treatment, 175–178
- cyclooxygenase-2 (COX-2), 101
- cyclophosphamide myeloablative regimens
 for aplastic anemia, 71
 with busulfan, 52
 for dysphagia/right hemiparesis, 249
 with fludarabine, 52
 for retroperitoneal fibrosis, 311
 for vasculitis, 304
- cyclosporine (CSA), 48, 135. *See also*
 Gengraf[®]; Neoral[®]; Sandimmune[®]
 for bile issues, 225
 cGVHD induced by, 72
 for chronic myelogenous leukemia,
 229
 clinical pharmacology, 106
 contraindications to usage, 128
 drug interactions, 107–108, 109
 evaluative studies, 120
 HLA-identical siblings, 75, 88–89
 with hydroxychloroquine (pediatric
 patients), 75
 intravaginal, for genital cGVHD, 213
 mechanism of action, 105–106
 methotrexate vs., 47
 pharmacokinetics
 absorption, 106
 distribution, 106–107
 metabolism, 107
 with prednisone, 127
 for retroperitoneal fibrosis, 311
 sGVHD induced by, 39, 40
 topical
 for vaginal restenosis, 211
 topical, for oGVHD cal, 204
 topical, for oral mucosal cGVHD, 191
 toxicity, 108

- CYP 3A4 inhibitors, 104. *See also* clarithromycin; ketoconazole
- cysteinyl leukotriene receptor-1 (cysLT1R) antagonists, 21
- cytokines
 - polymorphisms, 80
 - secretion by donor T cells, 10–11
- cytolytic T cells (CTLs), 32
- cytomegalovirus (CMV), 273–274
 - cardiac association, 308
 - as co-factor in GVHD development, 20
 - monitoring for, 129
 - prophylaxis of, 281–282
 - secondary, in oral cGVHD, 183
 - serositis association with, 305
 - in viral pneumonia, 273–274
- cytomegalovirus (CMV) gastrointestinal disease, 277
- cytopenia (single-/multilineage), patient evaluation, 238
- cytotoxic T lymphocytes (CTLs)
 - induction of apoptosis, 11
 - use of, by granule exocytosis pathways, 11
- daclizumab, 282, 379
- dapsone for *Pneumocystis jiroveci*, 281
- DBA anti-B6 cytolytic T cells (CTLs), 32
- DBA (H-2^d) strain pairing, 32
- DBY antigen, 20
- demyelinating disease (of CNS), 245–246, 247–249
- dendritic cells (DCs), 10, 17, 22, 134, 308, 361
- dermal appendage assessment, 57–61
- dermal sclerosis, 61, 66, 98, 169, 171
- dermatomyositis, 149
- diabetes mellitus, 295
- diagnostic criteria for establishment of cGVHD
 - bronchiolitis obliterans syndrome (BOS), 91, 234
 - cardiac involvement, 308
 - central nervous system (CNS), 247–249
 - gastrointestinal tract, 91, 217–218
 - genitalia, 91
 - hepatic cGVHD, 223–224
 - lungs, 91
 - mouth, 91
 - musculoskeletal/joints, 91
 - renal involvement, 310
 - skin, 91–8
- diarrhea, 73, 74, 89, 90, 125
- disability, defined, 252
- distinctive criteria seen in cGVHD. *See also* individual topic listings
 - eyes, 92
 - gastrointestinal tract, 92
 - hair, 92
 - hematopoietic/immunologic systems, 92
 - liver, 92
 - lungs, 92
 - mouth, 92
 - musculoskeletal system, 92
 - nails, 92
 - skin, 91–92
- DLCO (single-breath carbon monoxide testing method), 230
- DLI. *See* donor leukocyte infusions
- donor leukocyte infusions (DLI), 362
 - aGVHD/cGVHD association with, 31, 56, 360
 - for relapsed disease, and Scl-GVHD, 37
- donor T-cell activation (in acute GVHD), 8–10
 - activation by APCs, 8
 - TNF- α involvement, 12
- dry eye syndrome (DES), 64, 66–67, 87, 95, 158, 159–162. *See also* ocular GVHD
- dual energy x-ray absorptiometry (DEXA), 289
- dyspareunia, 209
- dysphagia, 124–125, 216
- dyspnea, 66, 91, 163, 230, 273, 305
- eczema vs. cutaneous cGVHD, 169
- edema/edema management, 260–262
- effector phase of GVHD, 11, 12
 - of skin GVHD, 35
- EIF1AY antigen, 20
- eIF-4E (eukaryotic initiation factor 4E)
 - binding protein phosphorylation, 110
- 8-methoxypsoralen (8-MOP), 379
- Elidel® (pimecrolimus cream), 176
- engraftment syndrome, 18
- enterovirus, 308
- EORTC QLQ-C30. *See* European Organization of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
- eosinophilia, 31, 48, 57, 80, 81
- eosinophilic fasciitis, 96–97, 117
- episcleritis, 201
- epithelial apoptosis, 8
- erythema nodosum leprosum (ENL), 111
- erythematous papular lesions (of cGVHD), 172
- esophageal complications (of gastrointestinal cGVHD)
 - diagnosis, 217–218
 - future advances, 219
 - incidence, 216
 - presentation, 216
 - prevention, 218–219
 - significance for prognosis, 216
 - therapy, site-specific, 218
- esophageal mucositis, 46
- estrogen replacement therapy, 162, 208, 211, 213, 290
- etanercept, 379
- European Group for Blood and Marrow Transplantation (EBMT) registry, 331, 361
- European Organization of Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), 253
- evaluation of cGVHD. *See also* assessment (clinical) of cGVHD; Karnofsky performance status (KPS) score; patient-reported outcomes (PROs) measurement
 - mouth evaluation, 57, 61
 - musculoskeletal/joints evaluation, 57, 66, 91
 - diagnostic criteria, 91
 - distinctive criteria, 92
 - ophthalmological evaluations, 66–67
 - photographic evaluation, 67–68
- evaluation of therapeutic response (in cGVHD). *See also* clinimetrics measurement
 - approach limitations, 149–151
 - characteristics, 147–146, 148–149
 - scale definitions, 148–149
- response criteria
 - challenges, 150
 - and diagnosis/staging, 147
 - importance of, 146
 - measurement selection indicators, 147–148
 - of NIH, 151–154. (*See also* National Institutes of Health)
 - future directions, 154–155
 - therapeutic outcomes, 149
- Exserohilum*, 276
- extracorporeal photopheresis (ECP), 18, 136–137, 162, 177, 235, 296, 379
- eyes. *See* ophthalmological issues
- FACT-BMT. *See* Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT)
- factor VIII glycoprotein, 240
- famciclovir for Varicella-Zoster virus (VZV), 276
- Fas TNF-receptor family, 11–12
 - activation of donor T-cells, 11
- fasciitis, 31, 169, 171
- Fialkow, P. J., 6
- fibroblastic periductal/periacinar stroma, 97
- fibrosis
 - multiple organs, 37
 - of skin, 31
 - effector phase of skin GVHD, 35
 - halofuginone blocking of, 35
 - processes implicated in, 20
- filamentary keratitis, 201
- fluconazole (azole drug class), 108, 129, 281
- fludarabine, 52, 269, 362
- fluticasone, 272

414 ■ INDEX

- Food and Drug Administration (FDA)
interest in PROs, 335
- Ford, C. E., 3, 6
- 4-aminoquinolines, 19–20
- FOXP3 antibody
activated T cell expression, 20, 121
mutations, 11
- fractures (of osteoporosis), management
of, 256
- Functional Assessment of Cancer Therapy-
Bone Marrow Transplant scale
(FACT-BMT), 253, 339
- Functional Assessment of Chronic Illness
Therapy (FACIT) portfolio, 339
- fungal disease, 274–275
- gallbladder and biliary problems, 224–225
- gastrointestinal GVHD, 124–125, 277
esophageal complications
diagnosis, 217–218
future advances, 219
incidence, 216
presentation, 216
prevention, 218–219
significance for prognosis, 216
therapy, site-specific, 218
in pediatric patients, 375
stomach, small intestine, colon
disorders
diagnosis, 221–222
future advances, 222
incidence, 219–221
presentation, 221
prevention, 222
significance for prognosis, 221
therapy, site-specific, 222
- G-CSF. *See* granulocyte colony stimulating
factor (G-CSF)
- gender consideration, 17
- genetic biomarkers for cGVHD, 80
- Gengraf®, 106
- genital cGVHD
clinical features of, 208
evaluation (clinical) of, 211–212
grading system, clinical, 208–209
histology of, 210–211
incidence of, 207
risk factors for, 208
symptoms/signs, 209–210
treatment/response, 211–213
- Giardia*, 277
- global scoring system, 56, 92–93
- glucocorticoid receptors (GR), 101, 102
inhibition of T cell proliferation, 102
- glucocorticoid-induced osteoporosis
(GIO), 130, 157, 255, 289
management of, 256–257
- glucocorticoids. *See* budesonide,
enteric-coated
evaluative studies, 120
pharmacokinetics
absorption, 103
distribution, 103
metabolism, 103–104
risks of, 129, 257
glucose intolerance, 126–127
steroid-induced, 246
- graft composition factors, 17
- graft vs. leukemia (GVL) activity, 6,
9–10, 79
- granule exocytosis pathways, 11
- granulocyte colony stimulating factor
(G-CSF)
causative for cGVHD, 71, 72
HCT donor pretreatment with, 11
PBSC association with, 360
peripheral blood mobilization, 17, 22
- granulomatous angiitis, 249
- Grover's transient acantholytic
dermatosis, 95
- Guillain-Barre syndrome, 245
- gynecological manifestations of cGVHD.
See genital cGVHD
- HA-1 antigen, 20
- halofuginone, 35
- haptoglobin, 79
- HCT. *See* hematopoietic cell
transplantation (HCT)
- Health Consensus Development Project on
Criteria for Clinical Trials in Chronic
Graft vs. Host Disease, 21–22
- health-related quality of life (HRQOL)
biomarker availability and, 79
cGVHD's impact on, 56, 68, 341–343
as clinical research endpoints, 253
conceptual model for long-term
transplant survivors, 337
ECP and, 137
functional status/symptoms vs.,
336–337
future research directions, 344
genital cGVHD and, 214
health status vs. preference-based
assessment, 343
interpretation issues, 343
measure selection criteria, 149, 151,
337–340, 343
health status vs. preference-based
assessment, 343
minimally important clinical
differences, 343
response shift, 343
timing of outcome assessment, 343
morbidity/mortality burden of cGVHD,
341–342
outcome evaluation, 344
QOL defined, 335–336
- heat-shock proteins (HSP), 101
- hematologic complications of cGVHD
clotting factors, 240
coagulation system abnormalities, 238
cytopenia, patient evaluation, 238
red blood cell abnormalities, 240–241
thrombocytopenia, 238–240
venous thromboembolism, 240
white blood cell abnormalities, 241
- hematopoietic cell transplantation (HCT).
See also allogenic hematopoietic stem
cell transplantation (allo-HSCT)
- cGVHD as barrier to success, 146
effects of conditioning with, 8, 9
HLA-identical HCT, 9
pediatric patients, 75
in pediatric patients, 376
pretreatment of donors with G-CSF, 11
- hematopoietic stem cell transplant
(HSCT), 3–4
for aplastic anemia, 6
effects of conditioning, 8
exogenous stimulus from, 6
onset of cGVHD after, 56
- Hemophilus influenzae*, 273
- hepatic cGVHD, 31
diagnosis, 223–224
future advances, 224
incidence, 222
in pediatric patients, 375
presentation, 222
prevention, 224
significance for prognosis, 222
therapy, site-specific, 224
- hepatic veno-occlusive disease. *See*
sinusoidal obstructive syndrome
(SOS)
- herpes simplex virus (HSV), 183, 277
- histocompatibility (minor) antigens, 20
- histologic studies
assessment utility of, 99
biopsies, results reporting, 98–99
liver, 97–98
oral, 97
overview, 94–95
skin, 96–97
- histopathological aspects of cGVHD,
93–13
- historical background
Chronic Graft Versus Host Disease, 5–4
classification/prognostic factors, 87–89
Graft Versus Host Disease, 4
hematopoietic stem cell transplant, 3–4
- HLA histocompatibility antigen. *See*
human leukocyte antigen (HLA)
system
- Hodgkin's disease, 246
- hormone replacement therapy (HRT), 208,
290. *See also* estrogen replacement
therapy; testosterone replacement
therapy
- human leukocyte antigen (HLA) system, 4
anti-HLA antibodies, 23
as biomarker in cGVHD, 21
class I differences, 10

- donor-recipient disparity, 71
 HLA-identical HCT, 9
 identical sibling donors, 46, 71, 75, 88–89
 chronic myelogenous leukemia case, 229
 mismatched transplants, 51–52
 human papilloma virus (HPV) disease, 214–207, 330
 H-Y antigens, 20
 hydrocortisone, 103
 for Cushing's syndrome, 293
 intravaginal, for genital cGVHD, 213
 hydroxychloroquine (HCQ), 19–20, 75, 128, 142, 272, 378
 hyperkeratosis, 201–202
 hyperlipidemia, 294
 hypertension, 126–127, 295
 hypoxemia, 273
- ichthyosis, 171
 imipenem for *Nocardia* infection, 273
 immune cytopenias, 56
 immune globulin, intravascular
 evaluative studies, 120
 for vasculitis, 304
 immune-mediated encephalitis, 249–250
 immunizations for infections
 in cGVHD, 278
 immunophilins, 101
 immunosuppressive therapies, 17, 31.
 See also azathioprine; calcineurin inhibitors; corticosteroids; cyclosporine; mycophenolate mofetil; sirolimus; tacrolimus
 approach to treatment, 125–126
 bile duct dropout (ductopenia)
 and, 98
 for BOS, 234–235
 combination regimens, 120
 discontinuation of, 124
 for gastrointestinal cGVHD, 218
 GVHD associated, 10, 12
 infections related to, 282–283
 local/low-dose systemic, 56
 low-dose radiation/chemotherapy, 52
 and new tumor development, 330
 prophylaxis combined with, 118–120
 recurrent malignancy risks, 128–129
 Seattle group revisions, 89
 sirolimus. (*See* sirolimus)
 topical medications, 57, 93
 2000-present trends, 49
 withdrawal of, 130
- incidence and trends of cGVHD
 1970–1980 data, 46
 1980–1990 data, 46–48
 1990–2000 data, 48–49
 2000-present data, 49
 future challenges, 52–53
 HLA-mismatched transplants, 51–52
- nonmyeloablative/reduced intensity conditioning transplants, 52
 peripheral blood vs. bone marrow grafts, 49–51
- infections in cGVHD
 bacterial infections. (*See* bacterial infections in cGVHD)
 central nervous system, 277–278
 complications from, 80, 117
 gastrointestinal, 277
 general concepts, 268
 prevention of, during cGVHD treatment, 129–130
 prophylaxis recommendations (*See* under bacterial infections in cGVHD)
 related to immunosuppression, 282–283
 respiratory infections. (*See* respiratory tract infections in cGVHD)
 skin/soft tissue, 276–277
 syndromic approach to patients, 268–270
 viral, 72
- Infectious Disease Society of America, 274
 inflammatory cytokines, 8, 21, 101–102
 inflammatory effectors, 12
 inflammatory gene polymorphisms, 80
 infliximab, 235, 282, 308, 379
 influenza, 129, 233, 273, 278, 282
 Institute of Medicine (IOM) Committee Report on Psychosocial Services to Cancer Patients/Families in a Community Setting recommendations, 398
 insulin resistance/diabetes mellitus, 295
 Intercultural Cancer Council, 404
 interferon-gamma (IFN- γ)
 acute GVHD association, 10
 predictive role in post-transplant GVHD, 79–80
 interleukin-2 (IL-2), 22
 response role in Graft vs. Host Disease induction, 10
 interleukin-4 (IL-4), 10
 interleukin-10 (IL-10), 10
 predictive role in post-transplant GVHD, 79–80
 International Bone Marrow Transplant Registry (IBMTR), 3, 88–89, 118, 361, 369
 International Classification of Functioning, Disability and Health (ICF), 252
 invasive aspergillosis, 275
 invasive fungal infection (IFI), 274
 IPEX syndrome (humans), 11
 itraconazole (azole drug class), 107, 129, 281
- Jacobsen, L. O., 3
 Japanese Marrow Donor Program (JMDP) Registry, 70
 Johns Hopkins Center, 377
- Karnofsky performance status (KPS) score, 73, 88, 89, 125, 137, 147
 keratoconjunctivitis sicca, 57, 92, 134, 158.
 See also ocular GVHD
 ketoconazole (azole drug class), 104, 107
Klebsiella pneumoniae, 273
 kyphoplasty (vertebroplasty), 256
- laboratory markers for prognosis of cGVHD
 donor APCs, 75
 minor histocompatibility antigens, 75
 OX40 expression, 74–75
 regulatory T cells, 75
 soluble biomarkers, 75
- lacrimal gland involvement, 31, 34, 202–203
 laser (CO₂, low-lever), for oral mucosal cGVHD, 191
 Lee cGVHD Symptom Scale (HRQOL measure), 339
 Lee Symptom Scale, 152
- leukemia
 acute leukemia, 361
 acute lymphoblastic leukemia (ALL), 369
 chronic lymphocytic leukemia study, 396–397
 chronic myeloid leukemia, 6, 72, 229, 361
 from HLA identical sibling donors, 46
 treatments for, 3
- Leukemia and Lymphoma Society, 400
 The Leukemia Society, 403
- lichen planus eruption, 5, 210
 characteristics of, 172–173
 cutaneous cGVHD, 169, 171
 genitals, 91
 oral, 91, 139, 182, 190
 PUVA treatment, 177
 of skin, 91, 172–173
 vulva, 210
- lichen sclerosus, 61
 lichen-planus-like sclerosis, 61, 91, 169, 182
 lidocaine (viscous), 190, 191
 limited/extensive chronic graft vs. host disease (cGVHD), 72–73, 88
 linezolid for *Nocardia* infection, 273
Listeria monocytogenes, 277
 liver. *See* hepatic cGVHD
 Lorenz, E., 3
 lungs and cGVHD, 17, 34
 bronchiolitis obliterans syndrome. (*See* bronchiolitis obliterans syndrome)
 chronic myelogenous leukemia (case study), 229
 cryptogenic organizing pneumonia clinical manifestation, 231–232
 diagnostic criteria, 231–233
 risk factors/epidemiology, 231
 therapy and outcome, 231–233

416 ■ INDEX

- lungs and cGVHD (cont.)
 diagnostic approach
 chest imaging, 230–231
 clinical assessment, 229–230
 procedures, 231
 pulmonary function testing, 230
- Lymphoma Research Foundation, 403
- Lymphoma Society, 403
- mast cells, 35
- Mathé, G., 6
- MD Anderson Symptom Inventory, 339
- Medical Outcomes Study (Short Form-12), 341
- meibomian gland dysfunction, 199, 201, 203
- memory (CD62L+) T cells, 9
- meropenem for *Nocardia* infection, 273
- metabolic effects of cGVHD
 bone metabolism
 avascular necrosis (AVN), 291–292
 osteopenia/osteoporosis, 289
 case presentations
 multi-focal AVN, 296
 sclerodermatous cGVHD, 297–298
 steroid refractory aGVHD, 296–297
 Cushing's syndrome/adrenal insufficiency, 292–293
 disturbed growth/development, 296
 thyroid function, abnormal, 295
- metabolic syndrome (MS), and components
 components
 hyperlipidemia, 294
 hypertension, 295
 insulin resistance/diabetes mellitus, 295
 obesity, 295
 definition and incidence, 293
 risk factors, 294
- metapneumovirus, 273
- methicillin-resistant *S. aureus* (MRSA), 273
- methotrexate
 for chronic myeloid leukemia, 229
 cyclosporine vs., 47
 100-day post-transplant data, 46
 leukoencephalopathy from, 247
 pediatric patients, 75
- methylprednisolone, 103, 104, 120, 128, 234, 250, 304
- metronidazole (antibacterial), 109
- MHCII+ antigen presenting cells (APCs), 35
- microangiopathic hemolysis, 241
- mineralocorticoid receptors (MR), 101
- minocycline for *Nocardia* infection, 273
- minor histocompatibility antigens (mHA), 9, 19
- mislabeling of symptoms as cGVHD, 57
- monitoring of cGVHD, 66–68. *See also* assessment (clinical) of cGVHD
 medical evaluations, 66
 medical photographs, 67–68
 ophthalmology evaluations, 66–67
 pulmonary function testing (PFT), 67
 monoclonal antibodies (MoAb) for pediatric cGVHD, 379
 mononeuritis multiplex, 246
 montelukast (cysLT1R antagonist), 21
 mortality (non-relapse) from cGVHD, 56
 MOS-SF-36 HRQOL measure, 339
- mouse models
 bone marrow transplant experiments, 3
 CpG ODNs response, 19
 inflammatory cytokines/receptors investigations, 13
 Th1/Tc1 vs. Th2/Tc2 responses, 18
- mouth evaluation, 57, 61
- moxifloxacin for *Nocardia* infection, 273
- mucosal carcinoma, 330–331
- mucositis, oral/esophageal, 46
- murine studies
 CNS complications post-allo-HSCT, 304
 of GVHD/MHC, 8–9, 17
 Th2 approximation, 18
- Murphy, J. B., 4
- musculoskeletal/joints evaluation, 57, 66, 91
 diagnostic criteria, 91
 distinctive criteria, 92
 in pediatric patients, 373–374
- myasthenia gravis (MG), 20, 216, 245, 262–263
 clinical course, 302
 diagnosis, 303
 future directions, 303
 incidence, 302
 site-specific therapy, 303
- mycophenolate mofetil (MMF), 108–109, 139–140
 drug interactions, 108–109
 for myasthenia gravis, 303
 for pediatric cGVHD, 377
 pharmacology/pharmacokinetics, 108
 for retroperitoneal fibrosis, 311
 for steroid-resistant cGVHD, 128
 toxicity, 109
- mycophenolic acid (MPA). *See* mycophenolate mofetil (MMF)
- myeloablative preparative regimens, 18, 46
 cyclophosphamide
 with busulfan, 52
 with fludarabine, 52
 HLA-identical siblings, 75
- myocarditis, 307
- naive (CD62L+) T cells, 9
- National Bone Marrow Transplant Link, 403
- National Bone Marrow Transplant Link (nbmtLINK), 399
- National Cancer Institute, 400
- National Institutes of Health, 5, 21–22.
See also Consensus Development Project on Criteria for Clinical Trials in cGVHD
 Ancillary Therapy and Supportive Care Working Group, 157
 categorization criteria, 56, 70, 151
 consensus on cGVHD, 31, 74
 grading/staging of GVHD, 11, 89–91
 retrospective validation, 99–100
 histologic criteria, 94
- National Marrow Donor Program (NMDP), 70, 73, 89, 399, 403
 HLA matching study, 51
 on PBSC grafts, 51
- natural killer (NK) cells
 elimination of host APCs, 10, 34
 role of, 21
 use of, by granule exocytosis pathways, 10
- natural killer T (NKT) cells, 21
 role of, 21
- nedocromil sodium, 35
- Neoral®, 106
- neuraminidase inhibitors for respiratory virus, 274
- neurological manifestations from cGVHD
 central nervous system (CNS)
 demyelinating disease, 247–249
 determination of cGVHD reality, 246–248
 immune-mediated encephalitis, 249–250
 proposed diagnostic criteria, 247–249
 stroke from vasculitis/angiitis, 249
- peripheral nervous system (PNS), 243–246
 myasthenia gravis, 20, 216, 245
 polymyositis, 98, 244–245
 post-transplant peripheral neuropathy, 245–246
- neutropenia, 6, 127, 139, 241, 273, 281, 379
- nitric oxide synthase (NOS2), 101
- Nocardia* infections, 273
- NOD2/CARD15 variants, 20, 24, 80
- nongenomic mechanisms, 103
- nonmyeloablative preparative regimens, 18, 38, 52, 295
- non-tuberculosis mycobacteria, 273
- norfloxacin (antibacterial), 109
- norovirus, 221, 277
- obesity, 224, 253, 293, 295
- ocular chronic graft vs. host disease (oGVHD)
 clinical manifestations, 199–202
 diagnosis/staging, 202–26
 management, 203–204

- bandage contact lens (BCTL), 203
 cyclosporine, topical, 204
 drainage, decrease of, 203–204
 evaporation control, 203
 flaxseed oil supplementation, 204
 lubrication, 203
 ocular surface inflammation,
 decrease of, 204
 steroids, topical, 204
 pathophysiology, 202–203
 in pediatric patients, 374
- ocular issues
 blepharitis, 201–202
 bulbar conjunctival hyperemia
 (“red eye”), 201
 cataracts, 126–127, 326–327
 cicatricial ectropion (of eyelids),
 201–202
 distinctive criteria, 92
 dry eyes. (*See* dry eye syndrome)
 episcleritis, 201
 evaluations, 57, 64–65, 66–67
 filamentary keratitis, 201
 hyperkeratosis, 201–202
 lacrimal gland involvement, 31, 34,
 202–203
 meibomian gland dysfunction, 201
 ocular sicca, 129
 pseudomembranous conjunctivitis, 199
 pseudomembranous
 keratoconjunctivitis, 202
 superior limbic keratoconjunctivitis, 201
 trichiasis, 201–202
- odynophagia, 124–125, 158, 160, 164
 Oncology Nursing Society, 404
 opioids, 191, 259
 oral chronic graft vs. host disease
 Consensus Development Project
 criteria, 187
 diagnosis, 187–24
 biopsy, 188
 histopathological/molecular features,
 183–21
 incidence, 182, 182–21
 management of, 189–190
 oral mucosal cGVHD. (*See* oral
 mucosal cGVHD)
 in pediatric patients, 182
 presentation, 182
 salivary gland cGVHD, 31, 34, 183–187
 management, 191–194
 treatment, 192
 sclerotic oral cGVHD, 187–23
 management, 194
 secondary cancer surveillance, 194
 significance, for prognosis/clinical
 course, 188
- oral issues
 destruction of lacrimal/salivary
 glands, 95
 distinctive criteria, 92
 dry mouth, 87
 evaluation, 57, 61, 91
 health care, 190
 histologic studies, 97
 oral sicca, 129
 in pediatric patients, 374
 treatments, 129
 xerostomia, 92, 185, 191
- oral mucosal cGVHD, 46
 management, 190
 symptoms, 182–20
 treatment, 24–193
- organ system monitoring, 157, 158–161
 orofacial sclerosis, 187
 oropharyngeal cGVHD, 216
 osteogenic sarcoma, 330
 osteonecrosis of the jaw (ONJ), 256
 osteopenia, 162, 165, 289, 296, 328
 osteoporosis, 126–127, 255–257
 clinical manifestations, 255–256
 glucocorticoid-induced, 130, 157, 255,
 256–257
 management of, 256
 fractures, 256
 and osteopenia
 definitions/incidence, 289
 pathophysiology/risk factors, 289
 treatment, 289–291
 risk factors, non-disease specific, 255
 as secondary/late effect, 328
- overlap syndrome, 57, 90, 117, 352
- p27^{kip1} (p27 kinase inhibitory protein 1), 110
 p70^{S6} (70-kD ribosomal S6) kinase
 phosphorylation, 109
 pamidronate, 256, 290, 296, 328
 pancreatic diseases
 cancer, 399
 diagnosis, 225
 incidence, 225
 presentation, 225
 prevention, 226–216
 significance for prognosis, 225
 therapy, site-specific, 225
- papular/papulosquamous rash, 61
 parenchymal disorders, 230
 parentgF1 cGVHD animal models, 32–34
 parentgF1 models, 32
 parent-into-F1 SLE-cGVHD model, 33–34
 pathophysiology of chronic graft vs. host
 disease
 B-cells, role of, 19
 chronic GVHD antigens, 20
 classification evolution, 23–24
 defined, 17
 complications, 31
 factors affecting, 17–18
 histopathological aspects of cGVHD,
 93–13
 pathogens, role in GVHD development,
 19–20
- T-cells, role of, 18
 Th1/Tc1 vs. Th2/Tc2 responses, 18
 thymic regulation, 18–19
- patient advocacy. *See* advocacy for patients
 Patient-Reported Outcomes Measurement
 Information System (PROMIS), 147,
 335, 344, 354, 357
- PBT. *See* peripheral blood transplantation
 (PBT)
- PDGF-BB (platelet-derived growth
 factor-BB) biomarker, 22
 PDGFR- α autoantibodies, 20
- pediatric cGVHD
 clinical manifestations
 cutaneous, 373–374
 eyes, 374
 gastrointestinal tract, 375
 hematopoietic system, 376
 immune system, 376–377
 liver, 375
 mouth, 374
 musculoskeletal, 373–374
 respiratory tract, 375–376
 incidence, 369–370
 issues in cGVHD
 cognitive development, 319–321
 dependency/overprotection, 319
 manifestations, 373
 MMF for steroid-resistant cGVHD, 128
 oral cGVHD, incidence of, 182
 pathobiology, 372–373
 predictive models of cGVHD, 75
 prednisone effects, 126–127
 preparative regimen, 372
 prevention, 377
 relapsed disease procedures, 70
 risk of cGVHD, 71
 salvage regimens
 anti-cytokine therapy, 379
 extracorporeal photopheresis.
 (*See* extracorporeal
 photopheresis (ECP))
 hydroxychloroquine (HCQ), 378
 monoclonal antibodies (MoAb),
 379
 mycophenolate mofetil, 377
 pentostatin, 377–378
 sirolimus, 377
 thalidomide, 379
 severe combined immune deficiency, 246
 sirolimus usage, 110
 soluble biomarkers, 75
 Spanish (Pediatric) Transplant group, 75
 stem cell source
 peripheral blood stem cells, 370–371
 umbilical cord blood, 371–372
 unrelated donors, 370
 supportive care, 380
 therapeutic trial study, 22
 toxicity/late effects, 379–380
 treatment, 377

418 ■ INDEX

- pentamidine (IV) for *Pneumocystis jiroveci*, 276
- pentostatin, 142, 269, 283, 377–378
- periacinar stroma, 97
- pericardiocentesis for serositis, 306
- peripheral blood stem cells (PBSCs)
 - bone marrow transplants vs., 52–53, 360–362
 - donor association with cGVHD, 21
 - elevations, in aGVHD, 12
 - G-CSF association, 360
 - G-CSF mobilization, 17, 22, 71
 - impact on cGVHD, 360–362
 - and incidence of aGVHD/cGVHD, 71–72
 - prevention of GVHD, 11
 - as source in pediatric cGVHD, 370–371
 - as stem cell source, 37, 71
 - Treg cell measurement, 20
 - women and, 207
- peripheral blood transplantation (PBT), 22, 71, 72, 120, 158
- peripheral nervous system (PNS)
 - manifestations of cGVHD, 243–246
 - myasthenia gravis, 20, 216, 245
 - polymyositis, 98, 244–245
 - post-transplant peripheral neuropathy, 245–246
- peripheral neuropathy, post-transplant, 245–246
- pharmacokinetics. *See also* individual drugs
 - calcineurin inhibitors
 - absorption, 106
 - distribution, 106–107
 - metabolism, 107
 - glucocorticoids
 - absorption, 103
 - distribution, 103
 - metabolism, 103–104
 - mycophenolate mofetil (MMF), 108
 - sirolimus
 - absorption, 110
 - distribution, 110
 - metabolism/elimination, 110
 - thalidomide
 - absorption, 113
 - distribution, 113
 - metabolism/elimination, 114
- pharmacology of cGVHD. *See also* individual drugs
 - calcineurin inhibitors. (*See* calcineurin inhibitors)
 - corticosteroids. (*See* corticosteroids)
 - glucocorticoids. (*See* glucocorticoids)
 - mycophenolate mofetil. (*See* mycophenolate mofetil)
 - sirolimus. (*See* sirolimus)
 - tacrolimus. (*See* tacrolimus)
 - thalidomide. (*See* thalidomide)
- pharyngeal candidiasis, 183
- photographic evaluation of cGVHD. *See* extracorporeal photopheresis (ECP)
- picornavirus, 273
- pilocarpine, 129
- pimecrolimus cream (Elidel®), 176
- plasmacytoid DC2 cells, 75, 177
- platelet antibodies, 20
- platelet-derived growth factor (PDGF), 20
- platelets/clotting factors in cGVHD, 238
- Pneumocystis jiroveci* (PCP), 271, 276
- Pneumocystis* pneumonia, 129, 157
- pneumonia. *See* bronchiolitis obliterans
 - organizing pneumonia; cryptogenic organizing pneumonia;
 - pseudomonas pneumonia
- pneumonitis, 305
- political effects of Chronic Graft Versus Host Disease, 4
- polyarteritis nodosa, 246, 304
- polymorphisms, cytokine gene/ inflammatory gene, 80
- polymyositis, 98, 244–245, 262
- posaconazole (azole drug class), 108, 129
- posterior leukoencephalopathy, 247
- post-transplant acute limbic encephalitis (PALE), 278
- predictive models for prognosis of cGVHD, 72–74
 - biomarkers
 - B cell function assessment, 81
 - genetic markers, 80
 - serum/cellular cytokine production and Th1/Th2 paradigm, 79–80
 - T cell function assessment, 80–81
 - clinical/research needs, 74
 - extensive skin involvement, thrombocytopenia, progressive onset (John Hopkins-II), 73
 - historical background, 87–89
 - Karnofsky performance status score, 88, 89
 - KBS, diarrhea, weight loss, cutaneous/ oral chronic GVHD (CIBMTR), 74
 - laboratory markers
 - donor APCs, 75
 - minor histocompatibility antigens, 75
 - OX40 expression, 74–75
 - regulatory T cells, 75
 - soluble biomarkers, 75
 - limited/extensive, 72–73, 88
 - model summary, 74
 - NIH consensus classifications, 74
 - onset type, 73
 - pediatric cGVHD, 75
 - progressive-type onset, elevated bilirubin/lichenoid histology (John Hopkins-I), 73
 - testing John Hopkins II in other data sets, 73–74
 - thrombocytopenia (Seattle), 73
- prednisolone, 102, 103, 256, 306
- prednisone, 103, 272
 - case studies, 160, 162
 - combined with
 - azathioprine, 125
 - calcineurin inhibitors, 101
 - cyclosporine, 127
 - hydroxychloroquine (pediatric patients), 75
 - thalidomide, 125
 - morbidity risks (long-term usage), 126–127
 - for myasthenia gravis, 302
 - onset, tapering, discontinuation of, 125–126
 - pediatric patients, 75
 - for polymyositis, 245
 - for primary adrenal insufficiency, 293
 - short-/long-term, 48
- prevention focus
 - ancillary and supportive care, 157–160
 - bacterial infections in cGVHD, 278–280, 280–281
 - community-acquired respiratory viruses (with antiviral agents), 282
 - IV immunoglobulin, 278–279
 - pneumocystis jiroveci prophylaxis, 281
 - prophylactic antibiotics, 279–280
 - VZV/HSV prophylaxis, 282
 - cutaneous cGVHD, 178
 - esophageal (of gastrointestinal cGVHD), 218–219
 - hepatic cGVHD, 224
 - pancreatic diseases, 226–216
 - pediatric cGVHD, 377
 - peripheral blood stem cells (PBSCs), 11
 - stomach, small intestine, colon disorders, 222
- primaquine for *Pneumocystis jiroveci*, 276
- primary biliary cirrhosis, 56, 98, 117
- pro-opiomelanocortin, 101
- prophylaxis methods (of cGVHD). *See also* immunosuppressive therapies
 - agnostic autoantibodies to PDGF receptor, 121
 - of bacterial infections, 278–280
 - antifungal prophylaxis, 280–281
 - antiviral prophylaxis, 281–282
 - community-acquired respiratory viruses (with antiviral agents), 282
 - IV immunoglobulin, 278–279
 - pneumocystis jiroveci prophylaxis, 281
 - prophylactic antibiotics, 279–280
 - VZV/HSV prophylaxis, 282

- Campath-1H antibody, 17, 48, 117
 combined immunosuppression,
 118–120
 corticosteroids. (*See* corticosteroids)
 cyclosporine. (*See* cyclosporine (CSA))
 immunomagnetic devices, 117
 methotrexate. (*See* methotrexate)
 prednisone. (*See* prednisone)
 regulatory T cells, 120–121
 removing/inactivating donor T cells
 T cell depletion *ex vivo*, 117–118
 T cell depletion *in vivo*, 118
 T cell depletion vs. unmanipulated
 transplants, 118
 stem cell source, 120
 tacrolimus. (*See* tacrolimus)
 T-cell depletion of donor marrow, 47
 Th2 cytokines (experimental), 11
 thalidomide. (*See* thalidomide)
 thymus tissue implants, 120
 timing of cGVHD, 117
 prostate cancer, 399
 Protopic® ointment, 176
 pseudomembranous conjunctivitis, 199
 pseudomembranous
 keratoconjunctivitis, 202
Pseudomonas, 273, 277
 pseudomonas pneumonia, 229
 psoralen and ultraviolet A therapy
 (PUVA), 128
 psoriasis vs. cutaneous cGVHD, 169
 psychiatric effects of cGVHD treatment, 317
 agitation, 317
 depression, 317
 mania, 317
 psychosocial issues in cGVHD
 caregiver needs, 322
 cognitive effects of treatment, 316–317
 concentration, 316–317
 memory, 316
 mood, 317
 demands of treatment/side effects
 activity limitations/work change,
 314–315
 family burden, 315
 needs based treatment response, 322
 overview, 314
 pediatric issues, 319–321
 cognitive development, 319–321
 dependency/overprotection, 319
 psychiatric effects of treatment, 317
 agitation, 317
 depression, 317
 mania, 317
 reactive emotions, 315–316
 anxiety, 315
 helplessness, 315–316
 uncertainty, 316
 worry, 315
 sexuality
 body image, 319
 genital/gonadal effects, 319
 lack of libido, 319
 social effects of treatment, 318
 altered physical appearance, 318
 disruption of social networks, 318
 extended caregivers demands, 318
 pulmonary function testing (PFT), 230
 pulmonary issues
 bronchiolitis obliterans organizing
 pneumonia. (*See* bronchiolitis
 obliterans organizing
 pneumonia)
 bronchiolitis obliterans syndrome.
 (*See* bronchiolitis obliterans
 syndrome)
 diagnostic criteria, 91
 distinctive criteria, 92
 morbidity/mortality in cGVHD, 80
 pulmonary function testing (PFT), 66
 pulmonary insufficiency, 46, 87
 secondary/late effects
 chronic obstructive lung
 disease, 327
 restrictive lung disease, 327
 pulse corticosteroid therapy, 103
 pure red blood cell dyscrasia, 245
 pure red cell aplasia (PRA), 240
 quadrivalent HPV-vaccine
 (GARDASIL®), 214
 quality of life (QOL). *See* health-related
 quality of life (HRQOL)
 radiation exposure (from atomic bomb), 3
 radiation related cancers, 330
 rapamycin (mTOR). *See* sirolimus
 reactive emotions to cGVHD
 anxiety, 315
 helplessness, 315–316
 uncertainty, 316
 worry, 315
 red blood cell abnormalities in cGVHD,
 240–241
 reduced intensity conditioning (RIC), 33,
 49, 52, 70, 182, 329, 362
 regulatory immune populations
 antigen presenting cells, 21
 biomarkers, 21–22
 immune reconstitution impact, 22–23
 inflammatory responses, 21
 macrophages, neutrophils, eosinophils, 21
 NK/NKT cells, 21
 Tregs, 20–21
 regulatory T cells, 11
 rehabilitation of cGVHD patients
 background information, 252
 complications/treatments
 contractures, 258–259
 edema, 260–262
 fatigue, 259–260
 evaluation assessments
 activities of daily living, 253
 Bone Marrow Survivor Study
 questionnaire, 253
 EORTC QLQ-C30, 253
 FACT-BMT, 253
 joint range of motion/muscle
 strength, 253
 quality of life measures, 253
 impact of organ system involvement
 arthritis/arthritis, 254
 avascular necrosis, 257
 fasciitis, 254–255
 musculoskeletal problems, 253–254
 osteoporosis, 255–257
 myasthenia gravis, 262–263
 neurological abnormalities, 257–258
 polymyositis, 262
 pulmonary rehabilitation, 258
 steroid myopathy (SM), 263
 weakness of patients, 262
 renal involvement in cGVHD
 clinical course, 309–310
 diagnosis, 310
 future directions, 310
 incidence, 309
 renal transplantation, 4
 respiratory syncytial virus (RSV), 273, 282
 respiratory tract infections in cGVHD,
 270–276
 bacterial pneumonia, 272–273
 blood and urine tests, 271–272
 bronchioalveolar lavage tests, 271–272
 diagnostic work-up, 271
 in pediatric patients, 375–376
 respiratory syncytial virus (RSV),
 273, 282
 sinusitis, 276
 viral pneumonia
 cytomegalovirus (CMV), 273–274
 fungal diseases, 274–275
 pneumocystis jiroveci (PCP), 276
 restrictive lung disease, 5–4, 327
 retinitis, 281, 305
 retinoids, 141–142
 retroperitoneal fibrosis
 clinical course, 310–311
 diagnosis, 311
 incidence, 310
 site-specific therapy, 311
 rheumatoid arthritis, 19, 117, 128, 149, 246
 ribavirin, inhaled, 274
 risedronate, 256–257, 290
 risk factors for cGVHD development, 18,
 47. *See also* acute chronic graft vs.
 host disease (aGVHD); aplastic
 anemia; chronic myeloid leukemia;
 peripheral blood stem cells (PBSCs)
 age of donor/recipient, 71
 conditioning regimen, 72
 cyclosporine A prophylaxis duration, 72
 HLA donor-recipient disparity, 71

420 ■ INDEX

- risk factors for cGVHD development (cont.)
 peripheral blood stem cell
 transplantation, 71–72
 previous aGVHD, 71
 skin/oral biopsy positive screening
 (post-HCT), 72
 stratification system (Johns Hopkins
 Center), 89
 tacrolimus prophylaxis, 72
 viral infections, 72
- rituximab, 141
 with corticosteroids, 240
 for myasthenia gravis, 303
 risks of, 223
 for steroid-resistant cGVHD, 48
 suppression of cGVHD progression,
 19, 33
- rotavirus, 221, 277
- RPS4Y antigen, 20
- salivary gland cGVHD, 31, 34, 183–187
 management, 191–194
 treatment, 192
- salmeterol inhalers, 272
- Salmonella*, 277
- salvage therapy in cGVHD
 anti-cytokine therapy, 142
 autologous transplantation, 142
 azathioprine, 135. (*See also*
 azathioprine)
 background information, 134
 calcineurin inhibitors, 135. (*See also*
 cyclosporine; tacrolimus)
 CD20 antagonists (rituximab), 141
 clofazimine, 141
 extracorporeal photopheresis.
 (*See* extracorporeal
 photopheresis (ECP))
 hydroxychloroquine, 19–20, 75,
 128, 142
 mycophenolate mofetil, 139–140.
 (*See also* mycophenolate mofetil)
 pentostatin, 142
 retinoids, 141–142
 sirolimus, 135–136. (*See also* sirolimus)
 thalidomide, 137–139. (*See also*
 thalidomide)
 topical phototherapy, 140–141
 total lymphoid irradiation (TLI), 140
- Sandimmune®, 106
- sB-cell activating factor (sBAFF), 22
- Scedosporium*, 276
- Schirmer's test (tear test), 5–4, 57, 64–65,
 66, 202
- sclerodermatous GVHD (Scl-cGVHD),
 17, 20, 56, 87, 117. *See also* B10.D2
 (or B6.C)gBALB/c animal model
 correlation with clinical cGVHD, 37
 manifestation data (1969–1976), 46
 neuropathic association (possible), 246
 survivors of, and allo-HSCT, 37
- sclerosing cholangitis, 34
- sclerosis
 cGVHD-associated, 21
 deep sclerosis, 67, 68, 91
 frank sclerosis, 32
 lichen sclerosis, 97, 151
 pulmonary restriction from, 66, 92
 skin sclerosis, 46, 61, 99
 systemic, 37, 98, 149
- sclerotic oral cGVHD, 187–23
 management, 194
- scoring system
 global, 56, 92–93
 individual organ systems, 92
- secondary and late effects
 bones/joint complications
 avascular necrosis (AVN), 328
 osteoporosis, 328
 malignancies, 328–331
 lymphomas, 329
 post allogeneic SCT leukemia, 329
 solid tumors
 pathogenesis, 330
 skin/mucosal carcinoma,
 330–331
 thyroid carcinoma, 331
 treatment/prevention, 331
 ocular (non-malignant late effects),
 326–327
 pulmonary effects, 327
- serositis, 125, 302
 clinical course, 305–306
 diagnosis, 306
 future directions, 306
 incidence, 305
 site-specific therapy, 306
- serum amyloid (SAA), 79
- severe combined immune deficiency
 (SCID), 246
- sexuality and cGVHD
 body image, 319
 genital/gonadal effects, 319
 lack of libido, 319
- Shigella*, 277
- sialogogue therapy, 129
 for salivary cGVHD, 191
- sicca syndrome, 5–4, 23, 46, 117, 129,
 201, 217
- Sickness Impact Profile (HRQOL
 measure), 339
- Simonson, M., 4
- sinusoidal obstructive syndrome
 (SOS), 12
- sirolimus, 109–111
 drug interactions, 111
 for pediatric cGVHD, 377
 pharmacokinetics
 absorption, 110
 distribution, 110
 metabolism/elimination, 110
 pharmacology, 109–110
- therapeutic monitoring, 110–111
 toxicity, 111
- site-specific therapy
 for esophageal complications, 218
 for hepatic cGVHD, 224
 for myasthenia gravis, 303
 for pancreatic diseases, 225
 for stomach, small intestine, colon
 disorders, 222
 for vasculitis, 304
- Sjögren's disease, 5–4, 6, 31, 56, 149, 303
- skin and soft tissues infections, 277–278
 dermal appendage assessment, 57–61
 skin carcinoma, 330–331
 skin fibrosis, 31
 effector phase of skin GVHD, 35
 halofuginone blocking of, 35
 processes implicated in, 20
- sleep issues, 259–260
 prednisone, high-dose, 126–127
- small intestine disorders. *See* stomach,
 small intestine, colon disorders
- social effects of cGVHD treatment, 318
 altered physical appearance, 318
 disruption of social networks, 318
 extended caregivers demands, 318
- soluble CD13 biomarker, 20
- Spanish (Pediatric) Transplant
 group, 75
- spirometric pulmonary testing, 230
- spleen derived products, 3
- staging for aGVHD, 147
- Staphylococcus pyogenes*, 276
- statins, 291, 294
- Stem Cell Trialists Group, 49
- stem cells
 bone-marrow derived, 33
 donor, engraftment of, 9
 epithelial, 12
 hematopoietic, 6
 memory stem cells, 9
 peripheral. (*See* peripheral blood stem
 cells (PBSCs))
 unrelated, and nonmyeloablative HCT
 regimens, 117
- steroid-resistant cGVHD, 48, 128
- stomach, small intestine, colon disorders
 diagnosis, 221–222
 future advances, 222
 incidence, 219–221
 presentation, 221
 prevention, 222
 significance for prognosis, 221
 therapy, site-specific, 222
- Streptococcus aureus*, 273, 276, 277
- Streptococcus pneumoniae*, 272, 277
- stroke (from vasculitis/angiitis), 249
- superior limbic keratoconjunctivitis, 201
- supportive care for cGVHD. *See* ancillary
 and supportive care
- syngeneic GVHD (sGVHD), 39

- systemic lupus erythematosus (SLE), 19, 32, 33–34, 117, 128, 303, 318
- systemic sclerosis, 37, 98, 149
- systemic vasculitis, 149
- T cells. *See also* Tregs (regulatory T cells)
- depletion of donor marrow prophylaxis, 47
 - function assessment
 - functional T cell assays, 80
 - immunological/molecular characterization, 80–81
 - prophylaxis involvement
 - regulatory T cells, 120–121
 - T cell depletion *ex vivo* (TCD), 117–118
 - T cell depletion *in vivo* (TCD), 118
 - T cell depletion vs. unmanipulated transplants, 118
 - role of
 - direct anti-antigen allogenic response, 18
 - Th1/Tc1 vs. Th2/Tc2 responses, 18
 - TH2 self (recipient)-reactive, 56
- T helper cells, 6, 72, 241
- tacrolimus (TAC), 48, 72, 135
- case studies, 160, 162
 - for chronic myelogenous leukemia, 229
 - clinical pharmacology, 106
 - contraindications to usage, 128
 - drug interactions, 107–108
 - mechanism of action, 105–106
 - pharmacokinetics
 - absorption, 106
 - distribution, 106–107
 - metabolism, 107
 - topical, for oral mucosal cGVHD, 191
 - toxicity, 108
 - for vasculitis, 304
- tacrolimus (TAC) ointment, 176
- target cell apoptosis, 8
- T-cell receptor excision circles (TRECs), 19
- telangiectasia, 169
- testosterone replacement therapy, 290
- TGF- β 1, 35
- Th1/Th2 cytokines, 11, 79–80
- TH2 self (recipient)-reactive T cells, 56
- thalidomide, 48, 111–114
- City of Hope/Stanford evaluation, 118–120
 - drug interactions, 114
 - neuropathy as side effect, 246
 - for pediatric cGVHD, 379
 - pharmacokinetics
 - absorption, 113
 - distribution, 113
 - metabolism/elimination, 114
 - pharmacology, 112–113
 - with prednisone, 125
 - toxicity, 114
 - trial (1995), 151
- T-helper type 1 subset (Th1)(secreting IL-1/IFN- γ), 10, 11
- T-helper type 2 subset (Th2)(secreting IL-4, IL-5, IL-10, IL-13), 10, 11
- thoracoabdominal irradiation (TAI), 140
- three-step model (in sequence), acute Chronic Graft Versus Host Disease (aGVHD)
- effects of HCT conditioning, 8
 - donor T-cell activation/cytokine secretion, 8–11
 - cytokine secretion by donor T-cells, 10–11
 - donor T-cell activation, 8–10
 - regulatory T-cells, 11
 - cellular and inflammatory effectors, 11–13
 - cellular effectors, 11–12
 - inflammatory effectors, 12
 - TLRs and innate immunity, 12–13
 - traffic of cellular effectors, 13
- thrombocytopenia in cGVHD, 238–240, 377
- thymic regulation, 18–19
- thyroid carcinoma, 331
- TMP/SMX for *Pneumocystis jiroveci*, 276
- TNF- α (tumor necrosis factor- α). *See also* TRAIL:DR4,5 ligand; TWEAK: DR3 ligand
- cardiac association, 308
 - induction of epithelial apoptosis, 8
 - predictive role in post-transplant GVHD, 79–80
 - prednisolone and, 102
 - role in acute GVHD pathophysiology, 12
- toll-like receptors (TLRs), 10
- and innate immunity, 12–13
 - Tlr4 gene, 12
 - TLR9, 19
- topical corticosteroids
- for cutaneous cGVHD, 176
 - for ocular GVHD, 204
 - for oral mucosal cGVHD, 190–191
 - for vaginal restenosis, 211
- topical phototherapy, 137, 140–141
- total body irradiation (TBI), 75, 245, 362
- in aplastic anemia/leukemia transplantation, 46
 - bone loss, 289
 - cGVHD vs., 326
 - in HCT conditioning, 8
 - in mice experiments, 3
 - pediatric risk factor, 320
 - renal impairment, 309
 - Schirmer's test results, 201
 - TB risk factor, 273
 - vs. conventional regimens, 52
- total lymphoid irradiation (TLI), 140
- toxoplasma, 277
- TRAIL:DR4,5 ligand, 11
- treatment. *See also* clinical trials for
- treatment testing, treatment methods; individual drugs of cGVHD, 125, 128. (*See also* cyclosporine; immunosuppressive therapies)
 - azathioprine, 125, 128
 - calcineurin inhibitors. (*See* calcineurin inhibitors)
 - goal of, 125
 - hydroxychloroquine, 19–20, 75, 128
 - immunosuppressive treatment approach, 126
 - infection prevention, 129–130
 - methylprednisolone, 103, 128
 - mycophenolate mofetil (MMF). (*See* mycophenolate mofetil)
 - outcomes, post-initial treatment, 130–132
 - prednisone (onset, tapering, discontinuation), 125–126
 - psoralen/ultraviolet A therapy (PUVA), 128
 - randomized treatment summaries, 125–126
 - secondary treatment indications, 130
 - systemic treatment indications, 124–125
 - of cutaneous cGVHD, 175–178
 - extracorporeal photopheresis (ECP). (*See* extracorporeal photopheresis (ECP))
 - phototherapy, 176
 - systemic retinoids, 178
 - topical corticosteroids/immunomodulators, 176
 - of oral mucosal cGVHD, 24–193
 - of salivary cGVHD, 192
- TRECs. *See* T-cell receptor excision circles (TRECs)
- Tregs (regulatory T cells), 23–24, 56
- as cGVHD prophylaxis, 120–121
 - deficiency of, 11
 - measurement in peripheral blood, 20
- trends of cGVHD
- 1970–1980, 46
 - 1980–1990, 46–48
 - 1990–2000, 48–49
 - 2000–present, 49
 - future challenges, 52–53
 - HLA-mismatched transplants, 51–52
 - nonmyeloablative/reduced intensity conditioning transplants, 52
 - peripheral blood vs. bone marrow grafts, 49–51
- triamcinolone 0.1% for cutaneous cGVHD, 176
- trichiasis, 201–202
- trimethoprim for *Pneumocystis jiroveci*, 276, 279
- trimethoprim/sulfamethoxazole (TMP/SMX), 279

422 ■ INDEX

- tuberculosis (TB), 273
 tumor necrosis factor- α . *See* TNF- α
 (tumor necrosis factor- α)
 tumors as secondary/late effect
 pathogenesis, 330
 skin/mucosal carcinoma, 330–331
 thyroid carcinoma, 331
 treatment/prevention, 331
 TWEAK: DR3 ligand, 11
- ulcers (in deep sclerosis), 61
 umbilical cord blood transplantation, 17,
 72, 364–366
 ursodeoxycholate, 129
 UTY antigen, 20
- vaccinations against infections, 129
 vaginal cGVHD. *See* genital cGVHD
 vaginal restenosis, 211
 vaginal stenosis, 207
 valgacyclovir, 129, 272, 276, 282
 Varicella-Zoster virus (VZV), 276, 277
- vasculitic neuropathies with mononeuritis
 multiplex, 246
 vasculitis
 clinical course, 303–304
 diagnosis, 304
 future directions, 304–305
 incidence, 303
 oral vasculitis, 5–4
 sensory multiple mononeuropathy
 from, 257
 site-specific therapy, 304
 stroke from, 249
 systemic vasculitis, 149
 venous thromboembolism in cGVHD,
 240, 328
 vertebroplasty (kyphoplasty), 256
Vibrio, 277
 viral infections as cGVHD risk
 factor, 72
 viral pneumonia
 cytomegalovirus (CMV), 273–274
 respiratory viruses, 273
- vitamin D supplementation, 130, 162, 163,
 164, 165
 voriconazole (azole drug class), 108, 129,
 275, 281
 vulvar burning, 209
 vulvar vestibulitis syndrome, 209
 vulvovaginal cGVHD. *See* genital cGVHD
- wasting syndrome, 56, 87
 weakness in patients with cGVHD, 262
 Weiden, P. L., 6
 weight loss, 34, 57, 73, 74, 89, 92, 124–125
 white blood cell abnormalities
 in cGVHD, 241
 Women's Health Initiative (WHI) study, 328
- xerosis, 171
 xerostomia, 92, 185, 191
- ZFY antigen, 20
 zoledronate (IV), 256, 290
 zoledronic acid, 165, 290